Dr.AddMedPHL said:ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase…
That reframing is the part I needed. Taking it to my next appointment.
Adding the clinical framing, because it changes how the question reads. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.
Ask again with the specifics and you will get a better answer than this one.
Dr.PathRoch said:NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.
Worth saying that the confident version of this is more useful to the person writing it than to the person reading it.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsThe figures, for anyone assembling their own picture. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.